Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label Extension Phase 3 Study to Evaluate the Long-Term Efficacy and Safety of LIB003 in Patients With HoFH and HeFH, CVD, or at High Risk for CVD, on Stable Lipid-Lowering Therapy Requiring Additional LDL-C Reduction

NCT04798430 is registered in ClinicalTrials.gov with LIB Therapeutics LLC as lead sponsor.

NCT NCT04798430
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04798430 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label Extension Phase 3 Study to Evaluate the Long-Term Efficacy and Safety of LIB003 in Patients With HoFH and HeFH, CVD, or at High Risk for CVD, on Stable Lipid-Lowering Therapy Requiring Additional LDL-C Reduction
Lead sponsor
LIB Therapeutics LLC
Phase
Phase 3
Overall status
Enrolling by invitation
Start date
December 3, 2020
Completion date
December 31, 2025
Enrollment
2,000 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

cardiovascular disease with mention of arteriosclerosis, elevated cholesterol, familial hypercholesterolemia